Indolent B-cell Lymphoma

• CLINICAL_TRIALS research · 2026-04-16
  Clinical Trial Update: Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 [Phase 1, Phase 2]

  Clinical trial evaluating autologous CD19-targeted T cells (CAR-T) for relapsed or chemotherapy-refractory chronic lymphocytic leukemia and …

• CLINICAL_TRIALS trial_result · 2026-01-29
  Clinical Trial Update: Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas [Phase 2]

  Phase 2 study evaluating acalabrutinib plus lisocabtagene maraleucel (Liso-Cel) in refractory/relapsed aggressive B-cell lymphomas, includin…

• CLINICAL_TRIALS trial_result · 2024-04-03
  Clinical Trial Update: A National Multicenter, Real-world Study of Linperlisib in the Treatment of Lymphoma [Phase 4]

  A Phase 4 real-world multicenter study evaluating linperlisib for indolent B-cell lymphoma is not yet recruiting.

• CLINICAL_TRIALS trial_result · 2023-03-31
  Clinical Trial Update: Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infection [Phase 2]

  A Phase 2 trial evaluated Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir in patients with indolent B-cell lymphoma associated with hepatit…

• CLINICAL_TRIALS trial_result · 2022-04-07
  Clinical Trial Update: Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma [Phase 2]

  Phase 2 trial evaluating rituximab in combination with pegylated interferon α-2b for indolent B-cell lymphoma is under investigation with st…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2018-04-12
  Clinical Trial Update: Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers [Phase 3]

  Phase 3 trial update on the efficacy and safety of ibrutinib in patients with chronic lymphocytic leukemia and indolent B-cell lymphomas who…

• CLINICAL_TRIALS trial_result · 2017-08-25
  Clinical Trial Update: Antiviral Agent HARVONI® for the Treatment of HCV-associated Indolent B-Cell Lymphoma [Phase 2]

  Phase 2 clinical trial update evaluating HARVONI for hepatitis C virus-associated indolent B-cell lymphoma.

• CLINICAL_TRIALS trial_result · 2015-02-23
  Clinical Trial Update: Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies [Phase 2]

  A Phase 2 feasibility study evaluating a 60-minute rapid infusion rituximab protocol in patients with indolent or intermediate-grade B-cell …